Drug for overactive bladder effective in patients who haven’t responded well to earlier therapy, study finds
NEW YORK — A drug made by Pfizer and used to treat overactive bladder was effective in reducing leakage of urine in patients with the disorder, according to the results of a post-approval clinical study.
Pfizer announced Friday results of a phase-4 study of Toviaz (fesoterodine fumarate) in the reduction of urge urinary incontinence in patients with OAB who had a less than 50% reduction in UUI when taking Detrol LA (tolterodine tartrate), a commonly prescribed treatment for the condition also made by Pfizer.
"This study adds to the body of evidence supporting Toviaz as an effective treatment of patients with overactive bladder, including patients who may not have responded to Detrol LA," Weill Cornell Medical College urology professor and principal study investigator Steven Kaplan said.
The 14-week study included 642 patients who were divided roughly in half into two groups, one of which received Toviaz and the other of which received placebo.
Study: No battle of the sexes when it comes to successfully quitting smoking
WASHINGTON — There is little difference between success in quitting smoking between men and women, according a recent study published in the journal Tobacco Control, the Society for Women’s Health Research announced Thursday. The theory had been that women were less successful than men, the researchers noted.
They did, however, find a pattern of sex differences in smoking cessation which was consistent. According to the study, “below age 50, women were more likely to have given up smoking completely compared to men, while among older age groups, men were more likely to have quit than women.” Different age groups had sex differences in smoking cessation but the authors are not sure what accounted for the finding.
Despite the findings of this new study, authors cautioned, the difficulty of smoking cessation based on sex should not be discounted. According to several studies, women experience more severe withdrawal symptoms than men when quitting smoking, which can make the act of quitting much harder and more uncomfortable for women. In addition, women are less likely than men to benefit from nicotine replacement therapy, according to the researchers, which also contributes to the difficulty some women experience when trying to quit.
It also is important to note that women who quit smoking relapse for different reasons than men. Weight control, stress and negative emotions are all reasons cited by women who have relapsed.
Paris Business Products seeks to bring Dotz cord identifiers to masses
WESTAMPTON, N.J. — A line of cord and cable management products is making its way to retailers nationwide.
Paris Business Products announced it has signed an exclusive license to manufacture and distribute the Dotz brand of cord and cable management products throughout North America. Dotz cord identifiers are designed to take the guesswork out of knowing what cord, cable or wire is in what plug and belongs to what device. Each identifier features a bright color and a preprinted insert, the company said.
"I am extremely excited to expand our product portfolio into a new and underserved category of cord and cable management products in retailers across North America. Dotz is a unique, well-designed product line that was ripe for wider distribution and expansion" Paris Business Products president and CEO Gerard Toscani said. "We provided an opportunity to Dotz LLC to bring a comprehensive, single-branded offering to our retail partners to cover the category."
Additional information about Dotz can be found here.